We and others have previously described epithelial-mesenchymal transition (EMT) as a frequent mechanism of de novo and acquired therapeutic resistance in mammary tumor cells, as well as all subtypes of NSCLC, including lung cancers with oncogenic driver mutations in EGFR and KRAS [45,46,47,48]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.